We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

391 hedge funds and large institutions have $9.56B invested in Neurocrine Biosciences in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 137 increasing their positions, 103 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more first-time investments, than exits

New positions opened: 109 | Existing positions closed: 41

65% more call options, than puts

Call options by funds: $93.9M | Put options by funds: $56.8M

33% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 103

18% more capital invested

Capital invested by funds: $8.09B → $9.56B (+$1.48B)

18% more funds holding

Funds holding: 332 → 391 (+59)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

1.37% less ownership

Funds ownership: 98.02% → 96.65% (-1.4%)

Holders
391
Holders Change
+59
Holders Change %
+17.77%
% of All Funds
7.7%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
109
Increased
137
Reduced
103
Closed
41
Calls
$93.9M
Puts
$56.8M
Net Calls
+$37.1M
Net Calls Change
+$33.9M

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$77M
2
BlackRock
BlackRock
New York
+$68.6M
3
State Street
State Street
Massachusetts
+$65.5M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$58.7M
5
Ameriprise
Ameriprise
Minnesota
+$34M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$138M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$118M
3
HM
HealthCor Management
New York
-$71.9M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$68.6M
5
O
OrbiMed
New York
-$66.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Chevy Chase Trust
376
Chevy Chase Trust
Maryland
$3K +$2.93K +28 New
CCA
377
Column Capital Advisors
Indiana
$3K +$3.67K +35 New
FMTCOCP
378
Farmers & Merchants Trust Co of Chambersburg PA
Pennsylvania
$2K – – –
TI
379
tru Independence
Oregon
$2K +$1.89K +18 New
OSAM
380
O'Shaughnessy Asset Management
Connecticut
$2K +$2.41K +23 New
BBHC
381
Brown Brothers Harriman & Co
New York
$1K -$419 -4 -40%
CFA
382
Carroll Financial Associates
North Carolina
$1K – – –
EI
383
Ellevest Inc
New York
$1K – – –
JWA
384
JFS Wealth Advisors
Pennsylvania
$1K – – –
AA
385
Argent Advisors
Louisiana
$1K +$1.05K +10 New
HR
386
Howe & Rusling
New York
$1K +$1.05K +10 New
LPWM
387
Lake Point Wealth Management
Texas
$1K +$1.15K +11 New
FDCDDQ
388
Federation des caisses Desjardins du Quebec
Quebec, Canada
$860 – – –
PGAM
389
Princeton Global Asset Management
New Jersey
$9 – – –
Artisan Partners
390
Artisan Partners
Wisconsin
– -$26.1M -289,942 Closed
SI
391
Sofinnova Investments
California
– -$17.3M -191,679 Closed
Balyasny Asset Management
392
Balyasny Asset Management
Illinois
– -$9.26M -102,759 Closed
Calamos Advisors
393
Calamos Advisors
Illinois
– -$8.71M -96,622 Closed
Adage Capital Partners
394
Adage Capital Partners
Massachusetts
– -$5.59M -62,000 Closed
LP
395
LMR Partners
United Kingdom
– -$4.21M -46,767 Closed
ECM
396
ExodusPoint Capital Management
New York
– -$4.03M -44,746 Closed
BFM
397
Boothbay Fund Management
New York
– -$2.62M -29,100 Closed
Assenagon Asset Management
398
Assenagon Asset Management
Luxembourg
– -$2.24M -24,885 Closed
Impax Asset Management Group
399
Impax Asset Management Group
United Kingdom
– -$1.98M -22,000 Closed
Simplex Trading
400
Simplex Trading
Illinois
– -$1.41M -13,502 Closed
14 15
16
17 18

NBIX Hedge Fund Activity: Q4 2019 in Review

391 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2019, worth a combined $9.56B — up 18% from $8.09B a quarter earlier.

Buyers outnumbered sellers: 109 funds opened new NBIX positions and 41 closed out — a net gain of 68 holders — while 137 added to existing stakes and 103 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $77M. The largest seller was Fidelity Investments, cutting an estimated $138M.

  • 391 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2019, up from 332 in Q3 2019.
  • Funds reported $9.56B of Neurocrine Biosciences stock for Q4 2019, up 18% quarter-over-quarter.
  • 109 funds opened new Neurocrine Biosciences positions in Q4 2019 and 41 closed out, a net change of +68 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $77M added.
  • The largest Neurocrine Biosciences seller in Q4 2019 was Fidelity Investments, an estimated $138M sold.

Based on aggregated 13F filings for Q4 2019.